## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.94 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($92.07)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. UBS Reiterates Buy Rating on Boston Scientific (BSX)**
- Source: Finviz | 20251221T094400 | Bullish | Relevance: 100%
- UBS has reiterated its "Buy" rating on Boston Scientific (BSX) with a $140 price target, despite a recent share drop. Analyst Danielle Antalffy believes the risk/reward profile is skewed to the upside, citing expectations for sustained momentum in high-growth areas and the CEO's commitment to grow divisions like Electrophysiology and the WATCHMAN device above market rates. UBS anticipates 2026 sales growth to exceed Boston Scientific's long-range target of 10-12%, primarily driven by the WATCHMAN business.

**2. UBS Reiterates Buy Rating on Boston Scientific (BSX)**
- Source: Insider Monkey | 20251221T094400 | Bullish | Relevance: 100%
- UBS has reiterated its Buy rating on Boston Scientific (BSX), maintaining a $140 price target, despite a recent dip in share price. Analyst Danielle Antalffy foresees an "increasingly skewed to the upside" risk/reward profile for BSX in 2026, driven by sustained momentum in high-growth areas and the CEO's commitment to growing key divisions. The company is expected to exceed its long-range sales growth target due to strong performance in its WATCHMAN business.

**3. Is Boston Scientific (BSX) One of the Best Healthcare AI Stocks to Buy Now?**
- Source: Insider Monkey | 20251222T150027 | Bullish | Relevance: 100%
- TD Cowen reaffirmed a Buy rating on Boston Scientific (BSX) and set a $115 price target, naming it their "Best Idea for 2026" due to its growth story in the medical devices sector. The company's long-range plan includes over 10% organic sales growth, 50 basis points of yearly operating margin expansion, and double-digit EPS growth, driven by key products like Farapulse and Watchman. Boston Scientific applies AI technologies such as machine learning and natural language processing to enhance medical imaging and patient management.

**4. Foster Victor Wealth Advisors LLC Has $19.35 Million Stake in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251221T150827 | Somewhat-Bullish | Relevance: 100%
- Foster Victor Wealth Advisors LLC increased its stake in Boston Scientific Corporation by 8.0% in Q3, now holding 198,778 shares valued at $19.35 million. The medical equipment provider exceeded Q3 earnings and revenue expectations, with analysts maintaining a consensus "Buy" rating and a $124.85 target price. Despite positive analyst sentiment and strong financial performance, company insiders have been net sellers, disposing of 143,095 shares worth approximately $14.23 million.

**5. Flputnam Investment Management Co. Buys 236,586 Shares of Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251221T114635 | Bullish | Relevance: 100%
- Flputnam Investment Management Co. significantly increased its stake in Boston Scientific Corporation by 237.8%, adding 236,586 shares to reach a total of 336,059 shares valued at $32.81 million. This move comes amidst broad "Buy" ratings from analysts and positive Q3 earnings for Boston Scientific, which exceeded estimates. The company has also provided optimistic FY2025 guidance, reinforcing investor confidence.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $120 | $130 | -8% |
| 2025-12-17 | Canaccord Genui | $131 | $132 | -1% |
| 2025-12-17 | RBC Capital | $130 | $125 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $143.0B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 27.8 |
| Current P/E | 31.8 |
| YoY Growth | 14.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.8% to -0.5% (+3.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.5pp (needs >4.0% for momentum thesis). Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 50. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.51% (CS: 41) | Neutral |
| RSI_14 | 49.7 | Neutral |
| MACD Histogram | 0.24 | Bullish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 0.978x | Below |
| vs SMA200 | 0.955x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $96.43
- **Stop Loss:** $92.07 (4.5% risk)
- **Target:** $105.15 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 275
- **Position Value:** $26,518.25
- **Portfolio %:** 26.52%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*